Skip to main content

Advertisement

SpringerLink
Log in

Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The purpose of this prospective, open-label, noncomparative, multicentre study was to evaluate the efficacy and safety of fluconazole in the treatment of hospitalised patients with mycoses. A total of 587 patients with diagnosed fungal infections were enrolled. Fluconazole was given orally or intravenously in a 200 or 400 mg loading dose, followed by 100 or 200 mg once daily. The most common candidal infections were fungemia, esophageal candidiasis, bronchopulmonary candidiasis, peritonitis, oropharyngeal candidiasis, urinary tract infection and deep wound infection. Meningitis was the most common cryptococcal infection. Of the 291 evaluable patients with candidiasis, 96% (70/73) of AIDS patients and 79% (171/218) of non-AIDS patients were clinically cured or improved. Of the 36 evaluable patients with cryptococcosis, 69% (20/29) of AIDS patients and 100% (7/7) of non-AIDS patients responded clinically. The overall mycological eradication rate was 85%; eradication was similar in patients with and without AIDS. Most adverse events during fluconazole therapy were mild to moderate in severity. This investigation confirms the results of previous studies demonstrating high response rates to fluconazole therapy in AIDS and non-AIDS patients with fungal infections. Even during long-term therapy treatment-limiting adverse events were uncommon with fluconazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Denning DW: Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. Journal of Antimicrobial Chemotherapy 1991, 28, Supplement B: 1–16.

    Google Scholar 

  2. Pfaller M, Wenzel R: Impact of the changing epidemiology of fungal infections in the 1990s. European Journal of Clinical Microbiology & Infectious Diseases 1992, 11: 287–291.

    Google Scholar 

  3. Richardson MD: Opportunistic and pathogenic fungi. Journal of Antimicrobial Chemotherapy 1991, 28, Supplement A: 1–11.

    Google Scholar 

  4. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. American Journal of Medicine 1991, 91, Supplement 3B: 72–75.

    Google Scholar 

  5. Milatovic D, Voss A: Efficacy of fluconazole in the treatment of systemic fungal infections. European Journal of Clinical Microbiology & Infectious Diseases 1992, 11, 395–402.

    Google Scholar 

  6. Hay RJ: Overview of the treatment of disseminated fungal infections. Journal of Antimicrobial Chemotherapy 1991, 28, Supplement B: 17–25.

    PubMed  Google Scholar 

  7. Diamond RD: The growing problem of mycoses in patients infected with the human immunodeficiency virus. Reviews of Infectious Diseases 1991, 13: 480–486.

    PubMed  Google Scholar 

  8. Perfect JR, Pickard WW, Hunt DL, Palmer B, Schell WA: The use of amphotericin B in nosocomial fungal infection. Reviews of Infectious Diseases 1991, 13: 474–479.

    PubMed  Google Scholar 

  9. Meunier F: Fluconazole treatment of fungal infections in the immunocompromised host. Seminars in Oncology 1990, 17, Supplement 6: 19–23.

    Google Scholar 

  10. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ: Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 1986, 104: 234–240.

    PubMed  Google Scholar 

  11. Hay RJ: Antifungal therapy and the new azole compounds. Journal of Antimicrobial Chemotherapy 1991, 28, Supplement A: 35–46.

    Google Scholar 

  12. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CU, Stern JJ, Feinberg J, Hafner R, Dismukes WE, the NIAID AIDS Clinical Trials Group, and the NIAID Mycoses Study Group: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1992, 326: 793–798.

    PubMed  Google Scholar 

  13. Powderly WG: Therapy for cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 1992, 14, Supplement 1: 54–59.

    Google Scholar 

  14. Humphrey MJ, Jevons S, Tarbit MH: Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy 1985, 28: 648–653.

    PubMed  Google Scholar 

  15. Arndt CAS, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG: Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. Journal of Infectious Diseases 1988, 157: 178–180.

    PubMed  Google Scholar 

  16. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. Reviews of Infectious Diseases 1990, 12, Supplement 3: 318–326.

    Google Scholar 

  17. Pasko MT, Piscitelli SC, Van Slooten AD: Fluconazole: a new triazole antifungal agent. DICP Annals of Pharmacotherapy 1990, 24: 860–867.

    Google Scholar 

  18. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE, the NIAID Mycoses Study Group, and the AIDS Clinical Trials Group: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New England Journal of Medicine 1992, 326: 83–89.

    PubMed  Google Scholar 

  19. Larsen RA, Leal MAE, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Annals of Internal Medicine 1990, 113: 183–187.

    PubMed  Google Scholar 

  20. Kujath P, Lerch K, Kochendörfer P, Boos C: Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993, 6: 376–382.

    Google Scholar 

  21. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD for the Candidemia Study Group and the NIAID Mycoses Study Group: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 1994, 331: 1325–1330.

    PubMed  Google Scholar 

  22. Cohen J: Treatment of systemic yeast infection with fluconazole. Journal of Antimicrobial Chemotherapy 1989, 23: 294–295.

    PubMed  Google Scholar 

  23. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, Potts D, Shelton M, Sugar A: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. American Journal of Medicine 1991, 91: 142–150.

    PubMed  Google Scholar 

  24. Ikemoto H: A clinical study of fluconazole for the treatment of deep mycoses. Diagnostic Microbiology and Infectious Diseases 1989, 12: 239S-247S.

    Google Scholar 

  25. Kauffman CA, Bradley SF, Ross SC, Weber DR: Hepatosplenic candidiasis: successful treatment with fluconazole. American Journal of Medicine 1991, 91: 137–141.

    PubMed  Google Scholar 

  26. Bren A, Kandus A, Lindi J, Varl J: Fluconazole in the treatment of fungal infections in kidney-transplanted patients. Transplantation Proceedings 1992, 24: 2765–2766.

    PubMed  Google Scholar 

  27. Diaz M, Negroni R, Montero-Gei F, Castro LGM, Sampaio SAP, Borelli D, Restrepo A, Franco L, Bran JL, Arathoon EG, Stevens DA, and other investigators of the Fluconazole Pan-American Study Group: A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clinical Infectious Diseases 1992, 14, Supplement 1: 68–76.

    Google Scholar 

  28. Robinson PA, Knirsch AK, Joseph JA: Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Reviews of Infectious Diseases 1990, 12, Supplement 3: 349–363.

    Google Scholar 

  29. Van't Wout JW, Mattie H, van Furth R: A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. Journal of Antimicrobial Chemotherapy 1988, 21: 665–672.

    PubMed  Google Scholar 

  30. Nolla-Salas J, León C, Torres-Rodríguez JM, Martín E, Sitges-Serra A: Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clinical Infectious Diseases 1992, 14: 952–954.

    PubMed  Google Scholar 

  31. Catanzaro A, Galgiani JN, Levine BE, Sharkey-Mathis PK, Fierer J, Stevens DA, Chapman SW, Cloud G, and the NIAID Mycoses Study Group: Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidiomycosis. American Journal of Medicine 1995, 98: 249–256.

    PubMed  Google Scholar 

  32. Galgiani JN, Catanzaro A, Cloud GA, Higgs J, Friedman BA, Larsen RA, Graybill JR, and the NIAID Mycoses Study Group: Fluconazole therapy for coccidioidal meningitis. Annals of Internal Medicine 1993, 119: 28–35.

    PubMed  Google Scholar 

  33. Graninger W, Prester E, Schneeweiss B, Teleky B, Georgopoulos A: Treatment ofCandida albicans fungaemia with fluconazole. Journal of Infection 1993, 26: 133–146.

    PubMed  Google Scholar 

  34. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, and the California Collaborative Treatment Group: High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 1994, 170: 238–242.

    PubMed  Google Scholar 

  35. Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, Dismukes WE, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: Treatment of blastomycoses with fluconazole: a pilot study. Clinical Infectious Diseases 1995, 20: 267–271.

    PubMed  Google Scholar 

  36. Presterl E, Graninger W, and a Multicentre Study Group: Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13: 347–351.

    Google Scholar 

  37. Bridge KS, Goodpasture HC: Disseminated histoplasmosis treated with fluconazole. Kansas Medicine 1994, 95: 113–115.

    PubMed  Google Scholar 

  38. Czwerwiec FS, Bilsker MS, Kamerman ML, Bisno AL: Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. American Journal of Medicine 1993, 94: 545–546.

    PubMed  Google Scholar 

  39. Kostiuk KA, Pons VG, Guglielmo BJ: Penetration of fluconazole into abscess fluid. Journal of Antimicrobial Chemotherapy 1994, 34: 603–605.

    PubMed  Google Scholar 

  40. Krcmery V, Jr, Trupl J, Krídl J, Danišovicovà A: Renal abscess and fungaemia due toTorulopsis glabrata: successful treatment with drainage and fluconazole. Clinical Infectious Diseases 1994, 18: 116.

    PubMed  Google Scholar 

  41. Levine J, Bernard DB, Idelson BA, Saunders C, Sugar AM: Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. American Journal of Medicine 1989, 86: 825–827.

    PubMed  Google Scholar 

  42. Simşek Ü, Akinci H, Oktay B, Kavrama I, Özyurt M: Treatment of catheter-associated candiduria with fluconazole irrigation. British Journal of Urology 1995, 75: 75–77.

    PubMed  Google Scholar 

  43. Sugar AM, Saunders C, Diamond RD: Successful treatment ofCandida osteomyelitis with fluconazole. Diagnostic Microbiology and Infectious Diseases 1990, 13: 517–520.

    Google Scholar 

  44. Schwartz DN, Fihn SD, Miller RA: Infection of an arterial prosthesis as the presenting manifestation of disseminated coccidioidomycosis: control of disease with fluconazole. Clinical Infectious Diseases 1993, 16: 486–488.

    PubMed  Google Scholar 

  45. Tacker JR: Successful use of fluconazole for treatment of urinary tract fungal infections. Journal of Urology 1992, 148: 1917–1918.

    PubMed  Google Scholar 

  46. Tang C: Successful treatment ofCandida albicans osteomyelitis with fluconazole. Journal of Infection 1993, 26: 89–92.

    PubMed  Google Scholar 

  47. Thakur RK, Skelcy KM, Kahn RN, Cannon L, Cherukuri R: Successful treatment ofCandida prosthetic valve endocarditis with a combination of fluconazole and amphotericin B. Critical Care Medicine 1994, 22: 712–714.

    PubMed  Google Scholar 

  48. Tunkel AR, Thomas CY, Wispelwey B:Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. American Joual of Medicine 1993, 94: 100–103.

    Google Scholar 

  49. Türker A, Altinörs N, Aciduman A, Demiralp O, Uluoglu U: MRI findings and encouraging fluconazole treatment results of intracranialCladosporium trichoides infection. Infection 1995, 23: 60–62.

    PubMed  Google Scholar 

  50. Urbak SF, Degn T: Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994, 208: 147–156.

    PubMed  Google Scholar 

  51. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA: Treatment of ocular fungal infections with oral fluconazole. American Journal of Ophthalmology 1995, 119: 477–481.

    PubMed  Google Scholar 

  52. Nightingale SD: Initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis with fluconazole. Archives of Internal Medicine 1995, 155: 538–540.

    PubMed  Google Scholar 

  53. Bennett JE: Antifungal agents. In: Mandell GL, Douglas RG, Bennett JE (ed): Principles and practice of infectious diseases. Churchill Livingstone, New York, 1990, p. 361–370.

    Google Scholar 

  54. National Institute of Allergy and Infectious Disease Mycoses Study Group: Treatment of blastomycosis and histoplasmosis with ketoconazole. Annals of Internal Medicine 1985, 103: 861–872.

    Google Scholar 

  55. Denning DW, Tucker RM, Hanson LH, Stevens DA: Treatment of invasive aspergillosis with itraconazole. American Journal of Medicine 1989, 86: 791–800.

    PubMed  Google Scholar 

  56. Phillips P, Fetchick R, Weisman I, Foshee S, Graybill JR: Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results. Reviews of Infectious Diseases 1987, 9, Supplement 1: 87–93.

    Google Scholar 

  57. De Wit S, Goossens H, Weerts D, Clumeck N: Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989, 1: 746–748.

    PubMed  Google Scholar 

  58. Laine L, Dretler RH, Conteas CN, Tuazon C, Koster FM, Sattler F, Squires K, Islam MZ: Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. Annals of Internal Medicine 1992, 117: 655–660.

    PubMed  Google Scholar 

  59. Meunier F, Aoun M, Gerard M: Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 364–368.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pfizer Central Research, 139NJ, Sandwich, Kent CT, UK

    P. F. Troke

Authors
  1. P. F. Troke
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

a Multicentre European Study Group

Additional information

Austria: W. Graninger (Vienna); Belgium: F. Meunier (Brussels), N. Clumeck (Brussels); France: B. Dupont (Paris), P. Dellamonica (Nice), G. Nitenberg (Villejuif), M. Gentilini (Paris), J. Frottier (Paris), J. Carlet (Paris), F. Vachon (Paris), W. Rozenbaum (Paris), J.L. Vilde (Paris), J.F. Acar (Paris), H. Kreis (Paris), J.P. Coulaud (Paris), C. Carbon (Paris); Germany: K.P. Hellriegel (Berlin), F. Holzmann (Frankfurt), G. Ehninger (Tübingen), D. Milatovic (Munich), K. Schumacher (Stuttgart), W. Stille (Frankfurt), H.J. Kolb (Munich), P. Kujath (Lubeck); Spain: L. Drobnic (Barcelona), G. Verger-Garau (Barcelona), F. Baquero (Madrid), A. Gil-Aguado (Madrid); Sweden: T. Linglof (Uppsala), J. Lindberg (Gothenburg), S. Cronberg (Malmo); Switzerland: F. Clara (Lugano); United Kingdom: R.J. Hay (London), J. Cohen (London), H. Grant Prentice (London), A.C. Newland (London), A.H. Goldstone (London), D.F. Gueret-Wardle (London).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Troke, P.F., a Multicentre European Study Group. Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 16, 287–295 (1997). https://doi.org/10.1007/BF01695633

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01695633

Keywords

Search

Navigation